- Home
- TYRA vs GSBC Comparison
TYRA vs GSBC Comparison
Compare TYRA & GSBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- GSBC
- Stock Information
- Founded
- TYRA 2018
- GSBC 1923
- Country
- TYRA United States
- GSBC United States
- Employees
- TYRA N/A
- GSBC N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- GSBC Major Banks
- Sector
- TYRA Health Care
- GSBC Finance
- Exchange
- TYRA Nasdaq
- GSBC Nasdaq
- Market Cap
- TYRA 667.3M
- GSBC 676.3M
- IPO Year
- TYRA 2021
- GSBC N/A
- Fundamental
- Price
- TYRA $12.11
- GSBC $62.59
- Analyst Decision
- TYRA Strong Buy
- GSBC Hold
- Analyst Count
- TYRA 8
- GSBC 2
- Target Price
- TYRA $31.00
- GSBC $60.50
- AVG Volume (30 Days)
- TYRA 243.4K
- GSBC 33.4K
- Earning Date
- TYRA 11-06-2025
- GSBC 10-15-2025
- Dividend Yield
- TYRA N/A
- GSBC 2.55%
- EPS Growth
- TYRA N/A
- GSBC 17.24
- EPS
- TYRA N/A
- GSBC 5.86
- Revenue
- TYRA N/A
- GSBC $224,299,000.00
- Revenue This Year
- TYRA N/A
- GSBC N/A
- Revenue Next Year
- TYRA N/A
- GSBC N/A
- P/E Ratio
- TYRA N/A
- GSBC $10.71
- Revenue Growth
- TYRA N/A
- GSBC 4.82
- 52 Week Low
- TYRA $6.42
- GSBC $47.58
- 52 Week High
- TYRA $29.60
- GSBC $68.02
- Technical
- Relative Strength Index (RSI)
- TYRA 54.50
- GSBC 56.33
- Support Level
- TYRA $11.70
- GSBC $62.52
- Resistance Level
- TYRA $12.91
- GSBC $63.81
- Average True Range (ATR)
- TYRA 0.67
- GSBC 0.90
- MACD
- TYRA -0.04
- GSBC -0.15
- Stochastic Oscillator
- TYRA 30.38
- GSBC 21.22
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About GSBC Great Southern Bancorp Inc.
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services. It operates into a single segment which is Community Banking.